|
What If Trial Participants Knew Their Contributions Were for Naught?
|
19 January 2023 |
|
Why Retractions Are On The Rise
|
19 January 2023 |
|
Developing a tool for detecting problematic RCTs in health systematic reviews: the INSPECT-SR project
|
19 January 2023 |
|
Introduction to the problem in Germany
|
19 January 2023 |
|
A possible solution for Germany
|
19 January 2023 |
|
Multi-modal cancer screening tests: hype or hope?
|
19 January 2023 |
|
Busting 2 zombie trials in a post-covid world.
|
17 November 2022 |
|
Which medicines should be used in cancer care? 1-12
|
17 November 2022 |
|
The wind that shook the Sugary Willows
|
17 November 2022 |
|
The waste in futile oncology drug development
|
10 November 2022 |
|
IP and access to health technologies
|
22 September 2022 |
|
Alternative Medicine
|
07 July 2022 |
|
Lessons from NICE
|
07 July 2022 |
|
Pathological Consensus
|
07 July 2022 |
|
Transformative Innovation Policy
|
07 July 2022 |
|
Event 4: Translation into Practice
|
07 July 2022 |
|
Predictive validity in drug discovery: what it is, why it matters and how to improve it
|
16 June 2022 |
|
HTA in Low-to-Middle-Income Countries
|
02 June 2022 |
|
NCI Involvement in Clinical Research
|
06 May 2022 |
|
Patient power in pricing disputes
|
06 May 2022 |
|
Institutionalizing systematic priority setting in LMIC
|
24 March 2022 |
|
Cancer in the Time of COVID and Conflict
|
04 November 2021 |
|
Prescrire: a critical eye on new drugs
|
14 November 2021 |
|
Who discovers medicines and what clinical benefit do they deliver to patients?
|
14 November 2021 |
|
HTA Evaluation Processes and Methods, Event 3
|
14 November 2021 |
|
Access to Multidisciplinary Cancer Treatment
|
14 November 2021 |
|
Regulation and HTA
|
14 November 2021 |
|
Promise and Unique Problems of CNS Drug Discovery
|
14 November 2021 |
|
Evidence Generation: Quality of data for decision-making
|
21 October 2021 |
|
Changing the landscape in rare disease
|
03 September 2021 |
|
Cost of Targeted Therapies in Cancer
|
03 September 2021 |
|
Quality Appraisal Tools
|
03 September 2021 |
|
Clinical and Economic Data Transparency: Process vs. Evidence
|
28 September 2021 |
|
Disclosure of R&D industry payments in Europe
|
28 September 2021 |
|
Is EBM being hijacked in oncology?
|
16 July 2021 |
|
Complex innovative trial designs: the good, the bad and the ugly
|
16 July 2021 |
|
Measuring what matters: patient involvement in HTA
|
12 July 2021 |
|
A genealogy of conflict of interest in medicine
|
08 July 2021 |
|
Challenges of Conducting Clinical Trials in Preventive Medicine
|
18 June 2021 |
|
Social hegemony: control of cancer agenda by Pharma
|
14 June 2021 |
|
Patient engagement in access to medicine
|
08 June 2021 |
|
Liquid biopsies for earlier detection of lung cancer, are we getting closer?
|
03 June 2021 |
|
EU Horizon Policy «Mission Possible»
|
21 May 2021 |
|
Value assessment in the US
|
18 May 2021 |
|
HTA and сlinical trials: fast and furious?
|
12 May 2021 |
|
Healthwatch-UK – fighting for better science
|
09 May 2021 |
|
How can your country end medical research waste?
|
07 May 2021 |
|
Public money for clinical research in oncology
|
07 May 2021 |
|
Master Observational Trials
|
07 May 2021 |
|
Mario Negri: a private non-profit research model
|
07 May 2021 |
|
Metrics for Evaluation of Scientific Slides
|
05 May 2021 |
|
What’s so special about zebras? The challenge of rare diseases
|
08 April 2021 |
|
Reading the literature with a critical eye
|
26 February 2021 |
|
Cancer care in the United States: the challenges of access and cost
|
01 January 2021 |
|
Perils of Peer Review
|
14 January 2021 |
|
What people get wrong about economics of the drug industry.
|
12 November 2020 |
|
The Dark Heart of Health Technology Assessment.
|
18 September 2020 |
